Evidence of clinical efficacy of a first generation CD19 CAR T cell in B cell malignancies.
EJHaem
; 4(3): 882-885, 2023 Aug.
Article
em En
| MEDLINE
| ID: mdl-37601889
ABSTRACT
The persistence and reactivity of CAR T cells were enhanced by adding co-stimulatory domains, which is the basis of currently approved CAR-T cell therapies. However, this comes at the expense of increasing toxicities from the strong cytokine release effect. This is the first report from anti-CD19 CAR-T cell therapy with a single activation domain to show a favourable safety profile and clinical efficacy with two patients who achieved durable responses up to 28 months in a cohort with heavily pretreated B cell malignancies.
Texto completo:
1
Bases de dados:
MEDLINE
Idioma:
En
Revista:
EJHaem
Ano de publicação:
2023
Tipo de documento:
Article